TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Buys $26,156.92 in Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary T. Szela bought 4,826 shares of the stock in a transaction dated Monday, January 27th. The shares were bought at an average cost of $5.42 per share, with a total value of $26,156.92. Following the completion of the purchase, the chief executive officer now directly owns 429,503 shares of the company’s stock, valued at approximately $2,327,906.26. This trade represents a 1.14 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

TriSalus Life Sciences Price Performance

TriSalus Life Sciences stock traded down $0.04 during midday trading on Wednesday, reaching $4.93. The company’s stock had a trading volume of 16,469 shares, compared to its average volume of 23,643. The stock has a market capitalization of $150.32 million, a P/E ratio of -1.98 and a beta of 0.51. The stock’s 50-day simple moving average is $4.55 and its 200-day simple moving average is $4.75. TriSalus Life Sciences, Inc. has a 52-week low of $3.50 and a 52-week high of $10.42.

Institutional Trading of TriSalus Life Sciences

A number of institutional investors have recently bought and sold shares of the stock. Walleye Capital LLC purchased a new position in shares of TriSalus Life Sciences in the third quarter worth $66,000. Virtu Financial LLC purchased a new position in TriSalus Life Sciences in the 3rd quarter worth $92,000. Vestcor Inc acquired a new stake in TriSalus Life Sciences during the 3rd quarter worth about $108,000. MSD Partners L.P. purchased a new stake in TriSalus Life Sciences during the 3rd quarter valued at about $184,000. Finally, Geode Capital Management LLC raised its stake in shares of TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after purchasing an additional 62,542 shares during the last quarter. 2.58% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TLSI has been the subject of several research analyst reports. Canaccord Genuity Group decreased their price target on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Northland Securities initiated coverage on TriSalus Life Sciences in a report on Friday, October 25th. They issued an “outperform” rating and a $12.50 target price for the company. Roth Mkm restated a “buy” rating and set a $11.00 price target on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Roth Capital upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Finally, Cantor Fitzgerald began coverage on shares of TriSalus Life Sciences in a report on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price target for the company. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $11.79.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.